Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568661 | 0.85 | ALDH1A1 (0.43) | SLC6A2SLC6A4ALDH1A1KDM4EMAPT | |
| SCHEMBL9631752 | 0.80 | ALDH1A1 (0.61) | SLC6A2SLC6A4ALDH1A1KDM4EMAPT | |
| SCHEMBL29217096 | 0.80 | ALDH1A1 (0.47) | SLC6A4ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL777382 | 0.80 | MAPK14 (0.42) | ALDH1A1KDM4EMAPTHPGDPDE7A | |
| SCHEMBL29722938 | 0.80 | MAPK14 (0.42) | ALDH1A1KDM4EMAPTHPGDPDE7A | |
| SCHEMBL3785288 | 0.78 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPTHPGDPDE7A | |
| SCHEMBL3521485 | 0.77 | PDE7A (0.54) | SLC6A2SLC6A4ALDH1A1KDM4EMAPT | |
| SCHEMBL810478 | 0.77 | ALDH1A1 (0.45) | SLC6A2SLC6A4ALDH1A1KDM4EMAPT | |
| SCHEMBL3790365 | 0.77 | KDM4E (0.55) | SLC6A2SLC6A4ALDH1A1KDM4EMAPT | |
| SCHEMBL3543388 | 0.77 | ALDH1A1 (0.40) | ALDH1A1KDM4EMAPTHPGDPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-8927544-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927544-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927544-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2013130958-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130958-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130231338-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231338-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231338-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | SLC6A2 4033/4885SLC6A4 4037/4885ALDH1A1 2723/4885 |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CCR5 | SLC6A2 2533/4885SLC6A4 1406/4885ALDH1A1 1991/4885 |
| US-20130231338-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CCR5 | SLC6A2 2533/4885SLC6A4 1406/4885ALDH1A1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.